ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1504

Association Between Anti-RNP Antibodies and Interferon Gene Expression but Not Complement Consumption in SLE

Erika Hubbard1, David Pisetsky2 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2Duke University Medical Center, Durham, NC

Meeting: ACR Convergence 2021

Keywords: Autoantibody(ies), complement, Gene Expression, interferon, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 9, 2021

Title: SLE – Etiology & Pathogenesis Poster (1480–1506)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Anti-nuclear antibodies are important serologic features of SLE and facilitate diagnosis. Anti-double stranded DNA (dsDNA) antibodies are routinely monitored for disease prognosis and are related to complement consumption, with immune complex deposition in the kidneys causing tissue damage. Relatively less is known about autoantibodies against RNA binding proteins (RBP) and about the relationship between either autoantibody and expression of the interferon (IFN) stimulated gene (ISG) signature. Extensive laboratory measurements from 2 clinical trials of tabalumab in SLE (ILLUMINATE 1&2) allowed analysis of the relationships between autoantibody levels, ISG expression, and complement (C) C3 and C4 levels.

Methods: Microarray data from 1620 active (SLEDAI≥6), female SLE patients and accompanying laboratory measurements were analyzed (GSE88884). All patients satisfied ≥4 of the 1997 ACR classification criteria. Gene Set Variation Analysis (GSVA) was carried out to determine enrichment of the ISG signature in each patient. Linear regression analysis was used to determine relationships between ISG GSVA scores and C3 and/or C4 levels as well as autoantibody levels. Unbiased classification and regression trees (CART) were constructed to determine the highest predictors of ISG expression.

Results: Patients were stratified by autoantibody positivity. Comparison of GSVA scores of the core IFN signature, shared by type I and type II IFNs, demonstrated that SLE patients positive for anti-ribonucleoprotein (RNP) antibodies alone had greater enrichment of ISG than those positive for anti-dsDNA alone (Figure 1). Similar results were noted for gene signatures of type I IFN, IFNα2, IFNβ, and IFNγ. In contrast, the TNF gene signature was observed comparably in patients with anti-dsDNA or anti-RNP antibodies and the IL-1 signature was only observed in those with anti-dsDNA. By linear regression, IFN GSVA scores and C3 and C4 levels were significantly, inversely related in patients with anti-dsDNA antibodies but not those with anti-RNP antibodies. Antibody levels correlated with decreased C levels in dsDNA+ patients. Additionally, ISG GSVA scores were increased in anti-dsDNA+ patients with low C3 or C4 compared to anti-dsDNA+ patients with high/normal C, but there was no significant difference in ISG expression in anti-RNP+ patients with the same stratification. CART analysis identified anti-RNP status was the highest predictor of ISG GSVA score. Finally, 56.2% of SLE patients without an ISG signature exhibited autoantibodies, but only 13.7% of SLE patients negative for autoantibodies expressed the ISG signature (Figure 2).

Conclusion: Taken together, these data indicate that anti-RNP antibodies are associated with ISG expression more strongly than anti-dsDNA antibodies, but are not related to the depression of C3 or C4. Furthermore, ISG expression is not required for autoantibody production, but autoantibodies are likely directionally related to the ISG signature.

Figure 1. ISG (A) and other inflammatory cytokine (B) enrichment in SLE patients with various autoantibodies. Violin plots display median values of GSVA enrichment (solid lines) and upper and lower quartiles (dashed lines). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 by Dunn's multiple comparisons test.

Figure 2. Autoantibody status was examined in IFN+ (GSVA enrichment score>0) and IFN- (GSVA enrichment score < 0) SLE patients in (A) whereas IFN status was examined in autoantibody-stratified patients in (B). Dunn’s multiple comparisons test determined significant differences in ISG enrichment among the groups displayed by violin plots. n.d.=no data.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001


Disclosures: E. Hubbard, None; D. Pisetsky, Immunovant, 2; P. Lipsky, Horizon, 2.

To cite this abstract in AMA style:

Hubbard E, Pisetsky D, Lipsky P. Association Between Anti-RNP Antibodies and Interferon Gene Expression but Not Complement Consumption in SLE [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/association-between-anti-rnp-antibodies-and-interferon-gene-expression-but-not-complement-consumption-in-sle/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-anti-rnp-antibodies-and-interferon-gene-expression-but-not-complement-consumption-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology